BAT Shareholders Digest a Busy Week: Capital Group Stake Slips, Goldman Turns Buyer, Organigram Bet Takes Shape

British American Tobacco packed a remarkable amount of corporate news into the first week of November, and the market's verdict on Friday was unkind — though not for any reason the company itself disclosed. The FTSE 100 heavyweight shed 2.5% as a broad flight from risk swept London equities, with Reuters linking the selloff to mounting anxiety over artificial intelligence. BAT closed the session at 54.84 €, and press coverage counted it among the leading fallers on the UK benchmark index.

Media commentary pointed to worries about declining volumes in traditional tobacco products, regulatory pressure and a rotation out of defensive consumer names as drags on the stock, with BAT faring worse than its own sector. Those explanations come from market reporting rather than from any company-confirmed trigger.

Capital Group's Holding Eases Just Below 18%

The same Friday brought a regulatory disclosure showing The Capital Group Companies had trimmed its voting stake in the cigarette maker. Its holding slipped from 18.023677% to 17.975584%, with the relevant threshold crossed on Wednesday. The mandatory filing puts Capital Group's reported position at roughly 387 million voting rights.

Goldman Switches to Buy, Lifts Target

Sentiment had received a more supportive nudge earlier in the week. On 2 November, according to media reports, Goldman Sachs upgraded BAT from "Neutral" to "Buy" and raised its twelve-month price target from 5,200 to 5,600 pence — changing both its recommendation and its valuation mark for the shares.

Buyback Correction Names Merrill Lynch as Counterparty

The buyback programme also generated paperwork. BAT reported on 2 November the repurchase of about 597,000 ordinary shares, bought between 26 and 30 October with the intention of cancelling them. On Tuesday the company corrected its 2 November disclosure of own-account transactions: Merrill Lynch International, not Goldman Sachs International, was named as the counterparty. All other details stood unchanged.

£100 Million Organigram Investment Tied to Aurora Deal

Further afield, Organigram Global said on 3 November that BAT, through subsidiary BT DE Investments Inc., had agreed a £100 million investment connected to Organigram's proposed acquisition of Aurora Cannabis. The tobacco group is to subscribe for 141 million Organigram shares at C$1.33 apiece. Completion is expected in January 2027, subject to the necessary approvals.

Board Changes and Insider Share Purchases

Governance news rounded out the period. BAT had announced on 28 October the appointment of Bruce Sewell as an independent non-executive director effective 1 January 2027, with committee changes due to take effect on 30 November 2026 and 1 January 2027. On 5 November the company also disclosed share purchases by seven executives under its Partnership Share Scheme, among them CEO Tadeu Marroco and COO Johan Vandermeulen — each acquiring three ordinary shares through the programme.